Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors

Edward M. Wolin, Amandine Manon, Christophe Chassaing, Andy Lewis, Laurent Bertocchi, Joel Richard, Alexandria T. Phan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Peptide drugs for antineoplastic therapies usually have low oral bioavailability and short in vivo half-lives, requiring less preferred delivery methods. Lanreotide depot is a sustained-release somatostatin analog (SSA) formulation produced via an innovative peptide self-assembly method. Lanreotide is approved in the USA and Europe to improve progression-free survival (PFS) in patients with unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and also approved in Europe for symptom control in carcinoid syndrome associated with GEP-NETs. This review discusses how the distinct molecule and formulation of lanreotide depot provide advantages to patients and health care providers, as well as the most recent clinical evidence demonstrating the safety and efficacy of lanreotide depot in inhibiting tumor growth and controlling hormonal symptoms in GEP-NETs. Methodology and Results: The lanreotide depot formulation confers a remarkable pharmacokinetic profile with no excipients, comprised only of lanreotide acetate and water. Of note, lanreotide depot constitutes an example for peptide self-assembly based formulations, providing insights that could help future development of sustained-release formulations of other antineoplastic peptides. Most patients with GEP-NETs will present with inoperable or incurable disease; thus, medical management for symptoms and tumor control plays a crucial role. Recent long-term clinical studies have demonstrated that lanreotide depot is well tolerated, prolongs PFS in GEP-NET patients, and significantly reduces symptoms related to carcinoid syndrome. Conclusions: The unique depot formulation and delivery method of lanreotide confer advantages in the treatment of metastatic GEP-NETs, contributing to improvements in NET-related symptoms and PFS without reducing quality of life in this patient population.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalJournal of Gastrointestinal Cancer
DOIs
StateAccepted/In press - Sep 13 2016
Externally publishedYes

Fingerprint

Neuroendocrine Tumors
Carcinoid Tumor
Antineoplastic Agents
Disease-Free Survival
Peptides
Therapeutics
lanreotide
Excipients
Somatostatin
Health Personnel
Biological Availability
Gastro-enteropancreatic neuroendocrine tumor
Neoplasms
Patient Care
Pharmacokinetics
Quality of Life
Safety
Drug Therapy
Water

Keywords

  • Depot preparations
  • Drug formulation
  • Lanreotide
  • Neuroendocrine tumors

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Wolin, E. M., Manon, A., Chassaing, C., Lewis, A., Bertocchi, L., Richard, J., & Phan, A. T. (Accepted/In press). Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors. Journal of Gastrointestinal Cancer, 1-9. https://doi.org/10.1007/s12029-016-9866-9

Lanreotide Depot : An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors. / Wolin, Edward M.; Manon, Amandine; Chassaing, Christophe; Lewis, Andy; Bertocchi, Laurent; Richard, Joel; Phan, Alexandria T.

In: Journal of Gastrointestinal Cancer, 13.09.2016, p. 1-9.

Research output: Contribution to journalArticle

Wolin, Edward M. ; Manon, Amandine ; Chassaing, Christophe ; Lewis, Andy ; Bertocchi, Laurent ; Richard, Joel ; Phan, Alexandria T. / Lanreotide Depot : An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors. In: Journal of Gastrointestinal Cancer. 2016 ; pp. 1-9.
@article{9c411c6d27f647dc9fbc6ebcc0d831f0,
title = "Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors",
abstract = "Purpose: Peptide drugs for antineoplastic therapies usually have low oral bioavailability and short in vivo half-lives, requiring less preferred delivery methods. Lanreotide depot is a sustained-release somatostatin analog (SSA) formulation produced via an innovative peptide self-assembly method. Lanreotide is approved in the USA and Europe to improve progression-free survival (PFS) in patients with unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and also approved in Europe for symptom control in carcinoid syndrome associated with GEP-NETs. This review discusses how the distinct molecule and formulation of lanreotide depot provide advantages to patients and health care providers, as well as the most recent clinical evidence demonstrating the safety and efficacy of lanreotide depot in inhibiting tumor growth and controlling hormonal symptoms in GEP-NETs. Methodology and Results: The lanreotide depot formulation confers a remarkable pharmacokinetic profile with no excipients, comprised only of lanreotide acetate and water. Of note, lanreotide depot constitutes an example for peptide self-assembly based formulations, providing insights that could help future development of sustained-release formulations of other antineoplastic peptides. Most patients with GEP-NETs will present with inoperable or incurable disease; thus, medical management for symptoms and tumor control plays a crucial role. Recent long-term clinical studies have demonstrated that lanreotide depot is well tolerated, prolongs PFS in GEP-NET patients, and significantly reduces symptoms related to carcinoid syndrome. Conclusions: The unique depot formulation and delivery method of lanreotide confer advantages in the treatment of metastatic GEP-NETs, contributing to improvements in NET-related symptoms and PFS without reducing quality of life in this patient population.",
keywords = "Depot preparations, Drug formulation, Lanreotide, Neuroendocrine tumors",
author = "Wolin, {Edward M.} and Amandine Manon and Christophe Chassaing and Andy Lewis and Laurent Bertocchi and Joel Richard and Phan, {Alexandria T.}",
year = "2016",
month = "9",
day = "13",
doi = "10.1007/s12029-016-9866-9",
language = "English (US)",
pages = "1--9",
journal = "Journal of Gastrointestinal Cancer",
issn = "1941-6628",
publisher = "Humana Press",

}

TY - JOUR

T1 - Lanreotide Depot

T2 - An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors

AU - Wolin, Edward M.

AU - Manon, Amandine

AU - Chassaing, Christophe

AU - Lewis, Andy

AU - Bertocchi, Laurent

AU - Richard, Joel

AU - Phan, Alexandria T.

PY - 2016/9/13

Y1 - 2016/9/13

N2 - Purpose: Peptide drugs for antineoplastic therapies usually have low oral bioavailability and short in vivo half-lives, requiring less preferred delivery methods. Lanreotide depot is a sustained-release somatostatin analog (SSA) formulation produced via an innovative peptide self-assembly method. Lanreotide is approved in the USA and Europe to improve progression-free survival (PFS) in patients with unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and also approved in Europe for symptom control in carcinoid syndrome associated with GEP-NETs. This review discusses how the distinct molecule and formulation of lanreotide depot provide advantages to patients and health care providers, as well as the most recent clinical evidence demonstrating the safety and efficacy of lanreotide depot in inhibiting tumor growth and controlling hormonal symptoms in GEP-NETs. Methodology and Results: The lanreotide depot formulation confers a remarkable pharmacokinetic profile with no excipients, comprised only of lanreotide acetate and water. Of note, lanreotide depot constitutes an example for peptide self-assembly based formulations, providing insights that could help future development of sustained-release formulations of other antineoplastic peptides. Most patients with GEP-NETs will present with inoperable or incurable disease; thus, medical management for symptoms and tumor control plays a crucial role. Recent long-term clinical studies have demonstrated that lanreotide depot is well tolerated, prolongs PFS in GEP-NET patients, and significantly reduces symptoms related to carcinoid syndrome. Conclusions: The unique depot formulation and delivery method of lanreotide confer advantages in the treatment of metastatic GEP-NETs, contributing to improvements in NET-related symptoms and PFS without reducing quality of life in this patient population.

AB - Purpose: Peptide drugs for antineoplastic therapies usually have low oral bioavailability and short in vivo half-lives, requiring less preferred delivery methods. Lanreotide depot is a sustained-release somatostatin analog (SSA) formulation produced via an innovative peptide self-assembly method. Lanreotide is approved in the USA and Europe to improve progression-free survival (PFS) in patients with unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and also approved in Europe for symptom control in carcinoid syndrome associated with GEP-NETs. This review discusses how the distinct molecule and formulation of lanreotide depot provide advantages to patients and health care providers, as well as the most recent clinical evidence demonstrating the safety and efficacy of lanreotide depot in inhibiting tumor growth and controlling hormonal symptoms in GEP-NETs. Methodology and Results: The lanreotide depot formulation confers a remarkable pharmacokinetic profile with no excipients, comprised only of lanreotide acetate and water. Of note, lanreotide depot constitutes an example for peptide self-assembly based formulations, providing insights that could help future development of sustained-release formulations of other antineoplastic peptides. Most patients with GEP-NETs will present with inoperable or incurable disease; thus, medical management for symptoms and tumor control plays a crucial role. Recent long-term clinical studies have demonstrated that lanreotide depot is well tolerated, prolongs PFS in GEP-NET patients, and significantly reduces symptoms related to carcinoid syndrome. Conclusions: The unique depot formulation and delivery method of lanreotide confer advantages in the treatment of metastatic GEP-NETs, contributing to improvements in NET-related symptoms and PFS without reducing quality of life in this patient population.

KW - Depot preparations

KW - Drug formulation

KW - Lanreotide

KW - Neuroendocrine tumors

UR - http://www.scopus.com/inward/record.url?scp=84987638423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987638423&partnerID=8YFLogxK

U2 - 10.1007/s12029-016-9866-9

DO - 10.1007/s12029-016-9866-9

M3 - Article

C2 - 27619395

AN - SCOPUS:84987638423

SP - 1

EP - 9

JO - Journal of Gastrointestinal Cancer

JF - Journal of Gastrointestinal Cancer

SN - 1941-6628

ER -